Thursday 28 July 2022

Reinfection, severe outcome more common with BA.5 variant; virus spike protein toxic to heart cells

Reinfection, severe outcome more common with BA.5 variant; virus spike protein toxic to heart cells

The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

Thousands of dead migrant seabirds wash up on Canada shore, avian flu suspected

The carcasses of thousands of migrant seabirds have washed up on the shores of eastern Canada this week and preliminary findings showed that the birds died of avian flu.

Cheap copies of GSK's HIV prevention drug could be ready in 2026

British drugmaker GSK has struck a deal to allow low-cost generic versions of its long-acting HIV preventive medicine to be used in the developing world, including sub-Saharan Africa where the virus remains a leading cause of death.

U.S. can conduct 60,000-80,000 monkeypox tests per week, HHS secretary says

The United States has the capacity to conduct 60,000-80,000 tests for monkeypox virus per week, Health and Human Services Secretary Xavier Becerra said on Thursday.

CVS siphoned millions from 'safety net' hospitals - New York lawsuit

New York on Thursday sued CVS Health Corp for allegedly forcing hospitals that serve low-income patients to pay millions of dollars to access discounted prescription drugs, violating state antitrust law.

Merck CEO concerned about proposed drug pricing bill hurting innovation

Merck & Co Chief Executive Rob Davis on Thursday raised concerns that a proposed bill to curb drug prices would hurt innovation, but said it would not impact sales of the company's top-selling drug and vaccine in the near-term.

Labcorp to spin off clinical-development business

Laboratory Corp of America Holdings said on Thursday it would spin off its wholly owned business focused on clinical drug trials, sending its shares up nearly 4%.

Altria's Juul stake goes up in smoke: from $12.8 bln to $450 mln

Marlboro maker Altria Group Inc on Thursday further slashed the value of its stake in Juul Labs Inc to just $450 million, blaming a decrease in the chances of the U.S. health regulator approving Juul's e-cigarettes.

Pfizer leaves COVID product forecast unchanged, shares fall

Pfizer Inc did not raise its 2022 forecast for sales of its COVID-19 vaccine and antiviral treatment on Thursday, and its shares fell nearly 5% before recovering.

Merck profit tops Wall Street view on strong Keytruda sales

Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue on strong sales of its blockbuster cancer immunotherapy drug.

Related Videos

Suicide prevention hotline launches nationwide

Pig heart transplants successful in brain-dead patients

Monkeypox could move into high-risk groups: WHO